148 related articles for article (PubMed ID: 24495942)
1. Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the EORTC Quality of Life Group.
Sodergren SC; White A; Efficace F; Sprangers M; Fitzsimmons D; Bottomley A; Johnson CD
Crit Rev Oncol Hematol; 2014 Jul; 91(1):35-46. PubMed ID: 24495942
[TBL] [Abstract][Full Text] [Related]
2. Practical management of tyrosine kinase inhibitor-associated side effects in GIST.
Joensuu H; Trent JC; Reichardt P
Cancer Treat Rev; 2011 Feb; 37(1):75-88. PubMed ID: 20570050
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
Nishida T; Doi T; Naito Y
Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib: new drug. For some gastrointestinal stromal tumours.
Prescrire Int; 2007 Aug; 16(90):138-41. PubMed ID: 17724833
[TBL] [Abstract][Full Text] [Related]
5. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
Crona DJ; Keisler MD; Walko CM
Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
[TBL] [Abstract][Full Text] [Related]
6. Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors.
Demetri GD
Semin Oncol; 2011 Apr; 38 Suppl 1():S10-9. PubMed ID: 21419931
[TBL] [Abstract][Full Text] [Related]
7. Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors.
Li J; Wang M; Zhang B; Wu X; Lin TL; Liu XF; Zhou Y; Zhang XH; Xu H; Shen LJ; Zou J; Lu P; Zhang D; Gu WJ; Zhang MX; Pan J; Cao H;
World J Gastroenterol; 2018 Dec; 24(46):5189-5202. PubMed ID: 30581268
[TBL] [Abstract][Full Text] [Related]
8. Acne rosacea associated imatinib mesylate in a gastrointestinal stromal tumor patient.
Demirci U; Coskun U; Erdem O; Ozturk B; Bilge Yilmaz I; Benekli M; Buyukberber S
J Oncol Pharm Pract; 2011 Sep; 17(3):285-7. PubMed ID: 20551113
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors.
Blanke CD; Huse DM
J Med Econ; 2010; 13(4):681-90. PubMed ID: 21067355
[TBL] [Abstract][Full Text] [Related]
10. [Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].
Nishida T; Omori T; Ueshima S
Gan To Kagaku Ryoho; 2011 May; 38(5):733-7. PubMed ID: 21566432
[TBL] [Abstract][Full Text] [Related]
11. Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT).
Yoo C; Ryu MH; Nam BH; Ryoo BY; Demetri GD; Kang YK
Eur J Cancer; 2016 Jan; 52():201-8. PubMed ID: 26699729
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors for Patients with Advanced Gastrointestinal Stromal Tumors.
Nerich V; Fleck C; Chaigneau L; Isambert N; Borg C; Kalbacher E; Jary M; Simon P; Pivot X; Blay JY; Limat S
Clin Drug Investig; 2017 Jan; 37(1):85-94. PubMed ID: 27665470
[TBL] [Abstract][Full Text] [Related]
13. Symptoms reported by gastrointestinal stromal tumour (GIST) patients on imatinib treatment: combining questionnaire and forum data.
den Hollander D; Dirkson AR; Verberne S; Kraaij W; van Oortmerssen G; Gelderblom H; Oosten A; Reyners AKL; Steeghs N; van der Graaf WTA; Desar IME; Husson O
Support Care Cancer; 2022 Jun; 30(6):5137-5146. PubMed ID: 35233640
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib-induced reversible purpuric rash in a patient with gastrointestinal stromal tumor.
Mutlu H; Büyükçelik A; Akça Z; Kaya N
J Oncol Pharm Pract; 2014 Aug; 20(4):298-301. PubMed ID: 23929730
[TBL] [Abstract][Full Text] [Related]
15. Gastric antral vascular ectasia in a patient with GIST after treatment with imatinib: case report and literature review.
Saad Aldin E; Mourad F; Tfayli A
Jpn J Clin Oncol; 2012 May; 42(5):447-50. PubMed ID: 22422898
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular effects of tyrosine kinase inhibitors used for gastrointestinal stromal tumors.
Chintalgattu V; Patel SS; Khakoo AY
Hematol Oncol Clin North Am; 2009 Feb; 23(1):97-107, viii-ix. PubMed ID: 19248973
[TBL] [Abstract][Full Text] [Related]
17. Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas.
Sethi TK; Keedy VL
Curr Treat Options Oncol; 2016 Feb; 17(2):11. PubMed ID: 26931561
[TBL] [Abstract][Full Text] [Related]
18. New therapeutic options in gastrointestinal stromal tumors.
Stein E; Aranha O; Agulnik M
Oncology (Williston Park); 2008 Feb; 22(2):206-11; discussion 215-6, 219. PubMed ID: 18409663
[TBL] [Abstract][Full Text] [Related]
19. Adherence to imatinib therapy in patients with gastrointestinal stromal tumors.
Blay JY; Rutkowski P
Cancer Treat Rev; 2014 Mar; 40(2):242-7. PubMed ID: 23931926
[TBL] [Abstract][Full Text] [Related]
20. Treatment of gastrointestinal stromal tumor after imatinib and sunitinib.
Montemurro M; Bauer S
Curr Opin Oncol; 2011 Jul; 23(4):367-72. PubMed ID: 21519258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
